

University for the Common Good



Increasing drug-related mortality over the last decade among Scotland's HCV-diagnosed PWID population

SA McDonald^{1,2}, A McAuley^{1,2}, DJ Goldberg^{1,2}, R Gunson³, P McIntyre⁴, K Templeton⁵, M Hickman⁶, SJ Hutchinson^{1,2}

¹Glasgow Caledonian University, ²Public Health Scotland, ³West of Scotland Specialist Virology Centre, ⁴Ninewells Hospital & Medical School, ⁵Edinburgh Royal Infirmary, ⁶University of Bristol



Disclosures

None

Background

- In Scotland, drug-related mortality (DRM) rates are rising steeply
 - Reaching 30/100,000 (15-64 yrs) in 2018 and 32/100,000 in 2019
 - Annual DR deaths: 474 rising to 1187 between 2008 and 2018
- DRM rates for England & Wales are 25% that for Scotland
- Scotland ranks high within the European and international context
- Reports of decreasing DRM rates among younger ages (15-29 years) suggested an ageing cohort effect, but other explanations, such as evolving drug choices, possible

Research objectives

- Describe trends in DRM rates among a large cohort of PWID who have been diagnosed with hepatitis C (HCV) infection
 - This analysis can address ageing cohort hypothesis, as age and calendar time effects can be distinguished
 - In Scotland, HCV predominantly affects people who inject drugs (PWID)
- Quantify associations between risk factors and DR mortality rates
 - To better understand DRM risk in the HCV-diagnosed population
 - Underscore need for co-location of HCV testing and management with addiction services → build on Scotland's HCV Action Plan

Methods

- Retrospective study of open cohort of PWID diagnosed with HCV in Scotland, 2008-2018
 - Record-linkage of HCV diagnosis database to deaths registry (National Records of Scotland)
 - 'Likely' PWID (PWID reported & acquisition risk not-known) 95.2% of HCV diagnoses
- ORM definition
 - Underlying or contributing cause according to ICD-10 categories
 - Drug disorders (F11-15,19), accidental or intentional self poisoning (X40-44, X60-64), assault by drugs (X85), poisoning: indet. (Y10-14)


Methods (2)

- Statistical analysis
 - Follow-up began on 1 Jan 2009; censoring earliest of death from non-DR cause, date of 65th birthday, date of migration, or 31 Dec 2018
 - Lexis expansion to estimate DRM rates for *attained* age
 - Poisson regression to estimate rate ratios (RRs) associated with attained age-group, adjusting for sex, referral setting for HCV testing, viraemic status, region, period HCV diagnosis (<2009, 2009-2018)
 - Multiple imputation methods to address missing data on risk factors other than age and sex

Sensitivity analyses

- Potential bias due to earlier diagnosed members of cohort having longer follow-up
 - Higher likelihood of ceasing drug use \rightarrow lower DRM rates
 - Censored follow-up at 3 years
- Restricted analysis to persons with *reported* injecting drug use as risk factor for HCV infection
 - Reduce heterogeneity by removing unknown (but likely small) number of never-injectors
- In addition, we conducted a complete-case analysis to compare to the principal results using multiple imputation


Study population flowchart



Results

- Among study population of 35,065 PWID:
 - 68% male, 36% aged <35 years at start of follow-up, 54% had been diagnosed with HCV <2009
 </p>
 - 1900 DR deaths occurred over 236 914 person-years of follow-up
 - Annual DR deaths: 101 rising to 342 between 2009 and 2018
- Most DR deaths (70%) were due to overdose
 - 43% of which due to combination of opioids and benzodiazepines and psychotropic substances


Results: DRM trend by attained age-group




Rising trend for all age-groups except 55-64 years

Effect of attained age disentangled from calendar time

Results: DRM trend by age-group, stratified by sex



Results: risk factor regression analysis



Results: sensitivity analyses

- Censoring follow-up at 3 years (n=337 deaths)
 Increasing DRM rate trend and persistent effects of attained age
- Restricting to persons with reported IDU as risk factor only
 Very similar DRM trend, but with slightly attenuated RRs
- Complete case analysis (n=31,073) consistent with main analysis

Summary

- Our findings within the HCV-diagnosed PWID cohort replicates increasing DRM trends at the population level in Scotland
 - DRM rates increased with age (up to 45-54 years)
 - Compared with 2011/12, DRM rates increased from 43% to 125% between 2015 through 2018
 - Low DRM and lack of trend in 55-64 years may indicated cessation of injecting or competing causes of death
- HCV cohort provides a denominator population for estimating DRM rates and investigating risk factor associations

Summary (2)

Limitations

- Did not adjust for socioeconomic inequalities (eg. deprivation)
- HCV acquisition risk data cannot distinguish between past and current injecting drug use
- Aggregating not-known with reported IDU risk may have underestimated the true DRM mortality rate among current PWID
- Rising DRM rates over the past decade in Scotland are not solely attributable to an ageing cohort effect.
- Strategies implemented for the elimination of HCV should also address the wider health harms among PWID

Acknowledgements

- Sheila M Bird for advising on statistical analysis
- Colleagues at Public Health Scotland who developed and maintain the national HCV Diagnosis database
- National Records of Scotland for the mortality register and Information Services Division for performing data linkage
- And, all the patients with a history of injecting drug use who appear on the HCV Diagnosis database